Table 1.
Characteristics of included studies
| Study | Date | Follow-up period | Patients | Intervention (MMF) | Intervention (CYC) | Definition of remission |
|---|---|---|---|---|---|---|
| Tuin J et al26 | 2019 | 4 years | MPA or GPA, relapse | 2 g/day | Oral CYC 2 mg/kg/day | BVAS=0 and CRP<10 mg/dL at 6 months |
| Jones RB et al27 | 2019 | 18 months | MPA or GPA, new diagnosis | 2 g/day (dose up to 3 g/day permitted) | Intravenous pulsed CYC 15 mg/kg every 2–3 weeks | BVAS=0 at 2 occasions apart within 6 months |
| Han F et al28 | 2011 | 6 months | MPA | 1.0 g/day (1.5 g/day if BW>70 kg) | Intravenous pulse CYC, 1.0 g/body monthly | BVAS=0 with PSL<7.5 mg/day at 6 months |
| Hu W et al29 | 2008 | 6 months | MPA or GPA, new diagnosis | 2.0 g/day (1.5 g/day if BW<50 kg) | Intravenous pulse CYC, 0.75–1.0 g/m2 body surface area monthly | BVAS=0 at 6 months |
BVAS, Birmingham Vasculitis Activity Score; CYC, cyclophosphamide; GPA, granulomatosis with polyangiitis; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; PSL, prednisolone.